Upstream Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $380.7M
- Price
- $6.95
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.46%
- Volume
- 30.3K
About
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Quick stats
Shares outstanding54.8M
Computed float25.6M
Float / shares46.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002022626
Websitehttps://upstreambio.com
AI Summary
AI-generated1/16
minorbullishearnings
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
Upstream Bio reported a Q2 net loss of $39.7 million, slightly narrower than the $40.0 million loss in the prior-year period, with cash, equivalents and short-term investments totaling $261.3 million.
The company stated its current cash resources are expected to fund planned operations through 2027 as it advances its lead asset verekitug.
Operationally, Upstream Bio remains on track to initiate Phase 3 trials in severe asthma and CRSwNP by the first quarter of 2027 and completed enrollment in its Phase 2 COPD trial with 481 participants.